MedTrace Logo

Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer

NCT00072410 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2023-10-04

Study results available
· View outcomes & findings →

Summary

RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells. Giving radiolabeled monoclonal antibody directly into the abdominal cavity may kill more tumor cells.

PURPOSE: Phase I trial to study the effectiveness of giving radiolabeled monoclonal antibody therapy directly into the abdominal cavity in treating patients who have advanced ovarian epithelial cancer.

Conditions

Interventions

BIOLOGICAL

90Y-hu3S193

Patients received a single dose of 10 mg of hu3S193 radiolabeled with the intended dose (mCi) of 90Y.

BIOLOGICAL

111In-hu3S193

Patients received a single dose of 5 mCi 111In-hu3S193 together with the 90Y-hu3S193.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Ludwig Institute for Cancer Research

    lead OTHER

Principal Investigators

  • Chaitanya R. Divgi, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-30
Primary Completion
2005-05-31
Completion
2006-11-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00072410 on ClinicalTrials.gov